The FDA has approved Rybrevant (amivantamab) in combination with chemotherapy to treat advanced, EGFR-mutant NSCLC that progressed on or after treatment with an EGFR TKI.

(HealthDay News) — Among cancer survivors, excess body weight is associated with an increased risk of a second primary cancer, according to a study published in JAMA Network Open.

The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Retifanlimab improved upon standard chemotherapy in patients with locally recurrent or metastatic anal cancer in a phase 3 ...

Adding radium-223 to treatment with enzalutamide and a bone-protecting agent improved rPFS and OS in patients with mCRPC and ...

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

Virtual palliative care has similar effects on quality of life as in-person care for patients with advanced non-small cell lung cancer.

Moderately hypofractionated nodal radiotherapy is not inferior to normofractionated radiotherapy for early breast cancer, data suggest.

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

Updated results from the INWORKS study “show the importance of adherence to the basic principles of radiation protection,” according to researchers.